title: Regulation of tissue factor-induced coagulation and platelet aggregation in flowing whole blood.
abstract: Photochemically induced thrombosis (a thrombin-dependent process) was measured in rats treated with moderate doses of anticoagulants, but which appeared to be unchanged. We considered the possibility that platelet-inhibiting agents, which also indirectly inhibit coagulation, would act as more potent antithrombotic agents. Inhibitors used as such were prostaglandin E1 (PGE1), which elevates cyclic AMP levels, and the P2Y12 ADP-receptor antagonist, AR-C69931MX. Effects of these agents were investigated in an ex vivo model system, in which whole blood under coagulant conditions was perfused over fibrinogen at defined wall shear rate. Perfusion of blood (rat or human) in the presence of tissue factor resulted in deposition of activated platelets and subsequent aggregate formation, along with exposure of procoagulant phosphatidylserine (PS) on the platelet surface and formation of fibrin fibers. In the presence of PGE1 aggregation was completely inhibited, but platelet adhesion and PS exposure were only party reduced, while fibrin formation was hardly affected. Treatment with AR-C69931MX caused similar, but less complete effects. These results indicate that in tissue factor-triggered blood under conditions of flow: (i) the platelet procoagulant response is independent of aggregate formation; (ii) the platelet-inhibiting effect of PGE1 and AR-C69931MX is sufficient to suppress aggregation, but not platelet adhesion and coagulation. These platelet inhibitors thus maintain their aggregation-inhibiting effect at sites of thrombin formation.
authors.affiliation: Department of Biochemistry, CARIM, University of Maastricht, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
authors.forename: Marijke J E
authors.initials: MJ
authors.lastname: Kuijpers
authors.forename: Cécile M A
authors.initials: CM
authors.lastname: Nieuwenhuys
authors.forename: Marion A H
authors.initials: MA
authors.lastname: Feijge
authors.forename: Willem
authors.initials: W
authors.lastname: Kloots
authors.forename: Peter L A
authors.initials: PL
authors.lastname: Giesen
authors.forename: Johann C
authors.initials: JC
authors.lastname: Jerling
authors.forename: Mirjam G A
authors.initials: MG
authors.lastname: oude Egbrink
authors.forename: Johan W M
authors.initials: JW
authors.lastname: Heemskerk
mesh_terms: D000249:Adenosine Monophosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D004195:Disease Models, Animal; D004347:Drug Interactions; D005337:Fibrin / Q000096:biosynthesis; D005340:Fibrinogen; D005343:Fibrinolytic Agents; D008297:Male; D010477:Perfusion; D010718:Phosphatidylserines / Q000378:metabolism; D015539:Platelet Activation; D010974:Platelet Aggregation / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D013917:Thrombin / Q000096:biosynthesis; D013925:Thromboplastin / Q000494:pharmacology*
chemical_list: D005343:Fibrinolytic Agents; D010718:Phosphatidylserines; D000249:Adenosine Monophosphate; C117446:cangrelor; D005337:Fibrin; D005340:Fibrinogen; D013925:Thromboplastin; D013917:Thrombin; D000527:Alprostadil